摘要
目的:探究依折麦布联合瑞舒伐他汀钙治疗冠心病合并高血压的效果及对血脂的影响。方法:回顾性分析2019年6月—2021年6月古田县医院收治的88例冠心病合并高血压患者的临床资料,按照治疗方式将患者分为两组,各44例。两组均行常规治疗,对照组给予瑞舒伐他汀钙片,观察组在对照组基础上加用依折麦布片,两组均连续服用6个月。比较两组治疗总有效率、不良反应发生率,治疗前后血脂、心功能指标水平变化。结果:观察组治疗总有效率为95.45%,高于对照组的81.82%,差异有统计学意义(P<0.05);治疗后两组甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)均降低,高密度脂蛋白胆固醇(HDL-C)升高,且观察组TG、TC、LDL-C低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05);观察组治疗后左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)水平低于对照组,左室射血分数(LVEF)水平高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:依折麦布联合瑞舒伐他汀钙治疗冠心病合并高血压效果显著,可有效调脂、改善心功能,且安全性较高。
Objective:To explore the effect of Ezetimibe combined with Rosuvastatin Calcium on coronary heart disease complicated with hypertension and its influence on blood lipid.Method:The clinical data of 88 patients with coronary heart disease complicated with hypertension admitted to Gutian County Hospital from June 2019 to June 2021 were retrospectively analyzed,and the patients were divided into two groups according to treatment methods,with 44 cases in each group.Both groups received conventional treatment,the control group was given Rosuvastatin Calcium Tablets,and the observation group added Ezetimibe Tablets to the control group,and both groups were taken continuously for 6 months.The total effective rate,incidence of adverse reactions,changes in blood lipid and cardiac function indexes before and after treatment were compared between the two groups.Result:The total effective rate of the observation group was 95.45%,which was higher than 81.82%of the control group,the difference was statistically significant(P<0.05).After treatment,triglyceride(TG),total cholesterol(TC)and low-density lipoprotein cholesterol(LDL-C)were decreased in both groups,and high-density lipoprotein cholesterol(HDL-C)was increased,and TG,TC and LDL-C in observation group were lower than those in control group,and HDL-C was higher than that in control group,the differences were statistically significant(P<0.05).After treatment,the levels of left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in observation group were lower than those in control group,and left ventricular ejection fraction(LVEF)was higher than that in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of Ezetimibe and Rosuvastatin Calcium is effective in the treatment of coronary heart disease complicated with hypertension,which can effectively regulate blood lipid and improve cardiac function,and has high safety.
作者
郑晨曦
李文闻
林义兆
ZHENG Chenxi;LI Wenwen;LIN Yizhao(Gutian County Hospital,Gutian 352200,China;不详)
出处
《中外医学研究》
2023年第21期153-156,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
冠心病
高血压
依折麦布
瑞舒伐他汀钙
Coronary heart disease
Hypertension
Ezetimibe
Rosuvastatin Calcium
